Diving into the Details of Upadacitinib for UC and Crohn’s Disease

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone’s Inflammatory Bowel Disease Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD With so many therapeutic options for Crohn’s disease and ulcerative colitis, it can be challenging to determine which one best matches your patient’s needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic landscape for inflammatory bowel disease.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sun-Ho Lee, MD, PhD Recent research explored the development, validation, and implications of the GEM integrative risk score (GEM-IRS). To learn how this innovative model helps predict the future risk of Crohn’s Disease in healthy first-degree relatives, Dr. Charles Turck speaks with Dr. Sun-Ho Lee, Assistant Professor and clinician scientist at the Inflammatory Bowel Disease Centre at Mount Sinai Hospital in Toronto, Canada.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Phil Ayers, PharmD, BCNSP, FMSHP, FASHP When considering multi-chamber bag parenteral nutrition (MCB-PN), there are a variety of factors to consider, including the patients’ hemodynamic stability and nutrient needs. After a patient is selected, their whole care team must be aware of common risks and challenges to ensure safe and effective delivery. Dr. Charles Turck is joined by Dr. Phil Ayers to discuss appropriate patient selection based on recent updates to ASPEN guidelines and safety considerations. Dr. Ayers is a Clinical Associate Professor at the University of Mississippi School of Pharmacy and the Chief of Clinical Pharmacy Services in the Department of Pharmacy at Baptist Medical Center in Jackson, MI.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Phil Ayers, PharmD, BCNSP, FMSHP, FASHP Though 100% soybean oil was once the standard for lipid emulsions in parenteral nutrition, mixed lipid emulsions have become more popular over the last decade. But there are a variety of patient-specific factors to consider before determining which type of lipid emulsion is appropriate. Dr. Charles Turck sits down with Dr. Phil Ayers to compare the available options and recommend strategies for selecting and monitoring patients. Dr. Ayers is a Clinical Associate Professor at the University of Mississippi School of Pharmacy and the Chief of Clinical Pharmacy Services in the Department of Pharmacy at Baptist Medical Center in Jackson.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD While neuromodulators are primarily used to treat psychiatric disorders, they can also help normalize symptoms of irritable bowel syndrome by targeting the gut-brain axis. In fact, about half of all patients with IBS have the potential to benefit from neuromodulators. Dr. Douglass Drossman joins Dr. Peter Buch to discuss his research on how various neuromodulators can provide relief for IBS patients. Dr. Drossman is the President of the Drossman Center of Education and Practice of Psychosocial Care and Drossman Consulting as well as a Professor Emeritus of Medicine and Psychiatry at the University of North Carolina School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Grady, MD While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kyle Staller, MD, MPH Join Dr. Peter Buch as he speaks with Dr. Kyle Staller, Director of the Gastrointestinal Motility Laboratory at Mass General and Assistant Professor of Medicine at Harvard Medical School, about uncovering the cause of a patient’s bloating and determining how to manage it.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kyle Staller, MD, MPH The complexities of gastroparesis can make the disease difficult to diagnose and treat. To help us overcome these challenges, Dr. Kyle Staller joins Dr. Peter Buch to share his preferred strategies for managing patients with gastroparesis. Not only is Dr. Staller an Assistant Professor of Medicine at Harvard University, but he’s also the Director of the GI Motility Lab at the Massachusetts General Hospital.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brian E. Lacy, MD, PhD About 50 percent of gastrointestinal providers are experiencing some degree of burnout, which can lead to a variety of personal and professional challenges. Joining Dr. Peter Buch to discuss the signs of burnout and what you can do to mitigate them is Dr. Brian Lacy, lead author of the “Burnout in Gastrointestinal Providers” article published in the American Journal of Gastroenterology in 2024.